Fractyl Health, Inc. (NASDAQ:GUTS) CEO Harith Rajagopalan Sells 96,517 Shares of Stock

Fractyl Health, Inc. (NASDAQ:GUTS) CEO Harith Rajagopalan sold 96,517 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $2.47, for a total transaction of $238,396.99. Following the sale, the chief executive officer now directly owns 491,329 shares in the company, valued at approximately $1,213,582.63. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Fractyl Health Stock Performance

NASDAQ:GUTS opened at $2.37 on Thursday. The firm has a market cap of $113.59 million and a price-to-earnings ratio of -0.19. Fractyl Health, Inc. has a 1-year low of $1.74 and a 1-year high of $14.50. The firm’s fifty day moving average price is $2.63 and its 200 day moving average price is $4.05. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.46 and a quick ratio of 7.46.

Fractyl Health (NASDAQ:GUTS) last released its earnings results on Tuesday, November 12th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.02. The firm had revenue of $0.01 million during the quarter. On average, sell-side analysts expect that Fractyl Health, Inc. will post -1.61 EPS for the current year.

Institutional Investors Weigh In On Fractyl Health

Several large investors have recently added to or reduced their stakes in GUTS. American International Group Inc. bought a new position in shares of Fractyl Health in the first quarter valued at approximately $9,911,000. M28 Capital Management LP acquired a new position in shares of Fractyl Health during the 1st quarter worth $13,735,000. Rhumbline Advisers bought a new position in Fractyl Health during the second quarter valued at about $32,000. Massachusetts Financial Services Co. MA raised its position in shares of Fractyl Health by 2.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 996,383 shares of the company’s stock valued at $4,255,000 after purchasing an additional 25,829 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in Fractyl Health in the 2nd quarter valued at approximately $61,000.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.